New hope for Hard-to-Treat lung cancer: experimental drug combo enters trial
NCT ID NCT07207395
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called JBI-802, either alone or with the immunotherapy pembrolizumab, in 30 adults with advanced lung cancer that has a specific genetic change (STK11 mutation). The main goals are to check safety and see if the treatment can shrink tumors or slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JBI-802 (an experimental drug) and pembrolizumab (an immunotherapy)
What this could lead to
If successful, this could offer a new treatment option for people with a specific type of lung cancer that has few effective therapies.
What could go wrong
This is an early Phase 2 trial with only 30 participants, so results may not apply broadly. The drug combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Christ Hospital
RECRUITINGCincinnati, Ohio, 45219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact